PHILADELPHIA BUSINESS JOURNAL | VenatoRx Pharmaceuticals has received $4.1 million — with the potential for millions more — from CARB-X.The money will be used to help develop a new class of oral antibiotics to treat infections caused by multi-drug-resistant Neisseria gonorrhoeae infections.